home > by publication type > daily analysis > Challenges Rise in the Fight Against TB
Email
| Prepared by: |
|---|
Treating drug-resistant strains has proved especially difficult due to cost. (AP Images/Mahesh Kumar A)
Andrew Speaker, an Atlanta lawyer infected with a highly drug-resistant strain of tuberculosis (XDR-TB), ignited a media firestorm and a minor health panic in the United States. His ability to enter the United States against the advice of the U.S. Centers for Disease Control called attention to problems with interagency coordination on infectious disease cases (PDF). Michael Osterholm, a disaster planning expert, said the case raises concerns about what would happen in “the opening days of a flu pandemic (USAToday).” Some health experts say the actual danger posed by the Speaker case was “overblown (AJC).” They add, however, that the risk posed by the rise of drug resistant TB is quite serious.
According to data from a report (PDF) by Doctors Without Borders, about nine million active infections of TB develop annually, leading to about two million deaths. TB is one of the most common infections among the HIV infected and the top killer of people with AIDS globally. A World Health Organization report finds the rise in drug-resistant TB strains corresponds with the world’s fastest-growing HIV infection rates. Multidrug resistant strains of TB (MDR-TB) are particularly deadly and number up to 424,000 annually, with XDR-TB infecting as many as 30,000. The XDR-TB strain is so drug resistant the estimated cure rate is only 30 percent. Its existence was confirmed just last year and has now been diagnosed in 37 countries. A 2007 report card from Global Health Advocates, a nonprofit group against "diseases of poverty," shows which countries are at "significant risk" of developing MDR-TB on a large scale.
Treating these strains is complicated because of the longer treatment time, increased side-effects, lack of effective secondary drug options, and significant financial cost. Drug treatments and diagnostic tests for TB are also several decades old. Health advocates point out that most drug research focuses on curing ailments common in the lucrative markets of the United States and Europe. But a new discussion is opening among pharmaceutical companies and nonprofit groups about the profitability of treating TB (BaltSun). “There’s more going on in TB drug development now than there has been in decades,” Al Hinman, a spokesman for the TB Alliance, told the Sun. Accordingly, the WHO recently laid out a $2 billion plan aiming to provide access to drugs and diagnostic tests to all MDR-TB and XDR-TB patients by 2015.
TB represents just one of several diseases emerging as a drug-resistant threat. For example, health advocates point to an alarming increase in the number of antibiotic resistant staph infections (Science Daily). A recent report (PDF) from the European Centre for Disease Prevention and Control notes that “antimicrobial resistance is one of the most serious public health problems, globally and in Europe.” Compounding this problem is the speed at which disease can now travel. A recent National Academies of Sciences report points out that disease can now circle the globe with “near telephonic speed, making long-distance connections and intercontinental infections almost as if by satellite.”
Weigh in on this issue by emailing CFR.org.
In Restoring the Balance: A Middle East Strategy for the Next President, experts from the Council on Foreign Relations and the Saban Center at the Brookings Institution propose a new, nonpartisan Middle East strategy drawing on the lessons of past failures to address both the short-term and long-term challenges to U.S. interests.
This report lays out a thoughtful agenda for U.S. policy toward the Democratic Republic of Congo, arguing that what happens there should matter to the United States--for humanitarian reasons as well as economic and strategic ones.
In this report, CFR Senior Fellow Michael A. Levi analyzes the potential use of deterrence in preventing terrorist groups from acquiring nuclear weapons and recommends a new approach to U.S. declaratory policy, as well as ways to improve U.S. capabilities to determine the sources of terrorist attacks.
Complete list of Council Special Reports.
This report argues that the United States must lead with domestic action on climate change and proposes a U.S. negotiating strategy for a global UN climate agreement that includes commitments from all major economies, while also promoting a less formal Partnership for Climate Cooperation that would focus the world's largest emitters on implementing aggressive emissions reductions.
This Task Force report examines changes in Latin America and in U.S. influence there, while taking account of the region's enduring importance to the United States. The Task Force offers an agenda for U.S. policy toward Latin America and identifies four critical areas that should provide the basis of a new U.S. approach.
About Independent Task Forces at CFR.
A selection of Foreign Affairs pieces by and about the preeminent political scientist of the last half century.
To order Task Force reports, Council Special Reports, and Critical Policy Choices, please call, fax, or order online from our distributor, the Brookings Institution Press: phone +1.800.537.5487, fax +1.410.516.6998.
For information on other reports that are not for sale, or for general publications information, please call +1-212-434-9516 or email publications@cfr.org.
To request permission to reuse Council materials, please email publications@cfr.org or fax +1.212.434.9859.
Please include the complete information of the requested work—author, title, sections/pages to be copied or reprinted, and number of copies to be made—along with a brief description of where and how you would like to reuse the work.
You may also request permission for Council material through Copyright Clearance Center. For more information, please click on the link below.
Copyright 2009 by the Council on Foreign Relations. All Rights Reserved.
Global Economy 